Unicycive Therapeutics, Inc. — fact timeline

Unicycive Therapeutics, Inc. shareholders approved Ratification of appointment of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2025-06-19 meeting.

“The appointment of Grassi & Co. CPAs, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 14,667,242 286,958 9,928 31”

Unicycive Therapeutics, Inc. shareholders approved Election of three nominees for director at the 2025-06-19 meeting.

“On June 19, 2025, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”).”

Unicycive Therapeutics, Inc. amended Amendment No. 2 to the Sales Agreement with Guggenheim Securities, LLC (effective 2026-06-05).

“On June 5, 2026, the Company entered into Amendment No. 2 to the Sales Agreement with the Agent (the “Amendment”) to increase the number of Shares that may be sold in the ATM Offering to $150,000,000.”

Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $(12.8) million loss, EPS $(0.54) per share of common stock.

“Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026”

Unicycive Therapeutics, Inc. reported the full year ended December 31, 2025 results: net income $26.6 million, EPS $1.67 per share of common stock.

“Net loss attributable to common stockholders for the year ended December 31, 2025 was $26.6 million, or $1.67 per share of common stock, compared to a net loss attributable to common stockholders of $37.8 million, or $5.65 per share of common stock for the same period in 2024.”

Unicycive Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-10 reverse stock split of Common Stock (effective 2025-06-18).

“On June 18, 2025, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split.”

Unicycive Therapeutics, Inc. reported the three months ended March 31, 2024 results: net income Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s, EPS $0.61 per share of common stock.

“Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”) , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced its financial results for the three months ended March 31, 2024”

Unicycive Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share.

“Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share of common stock, compared to a net loss of $18.1 million, or $1.20 per share of common stock, for the same period in 2022.”

Unicycive Therapeutics, Inc.: Filing of Certificate of Designation for Series B-1 Preferred Stock and Series B-2 Preferred Stock, setting forth rights, preferences, and limitations (effective 2024-03-14).

“Pursuant to the terms of the Purchase Agreement, on March 14, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 50,000 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock”

Unicycive Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Aggregate purchase price of $50 million for 50,000 shares of Series B Convertible Preferred Stock at (effective 2024-03-13).

“On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), 50,000 shares of its Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share with an initial conversion price of $1.00 per share, subject to adjustment (the “ Conversion Price”) , for an aggregate purchase price of $50 million.”

Unicycive Therapeutics, Inc.: Filed Certificates of Elimination for five series of preferred stock and an Amended Certificate of Designation for new Series A Preferred Stock (effective 2024-03-14).

“On March 13, 2024, the Company filed with the Delaware Secretary of State a Certificate of Elimination for each of the Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock and Series A-5 Convertible Preferred Stock. Each Certificate of Elimination was filed with an effective date of 12:01 a.m. ET on March 14, 2024.”

Unicycive Therapeutics, Inc. entered into Exchange Agreement with certain accredited investors (effective 2024-03-13).

“On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into an exchange agreement (the “ Exchange Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Investors surrendered an aggregate of 43,649,000 shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as “Series A-2 Prime Preferred””

Unicycive Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $0, EPS $0.13 per share of common stock.

“compared to five other commercially available phosphate binders. Financial Results for the Third Quarter Ended September 30, 2023 Licensing Revenues: Licensing revenues were $0 compared to $1.0 million for the same period in 2022, due to an upfront payment for a licensing agreement entered into with Lee’s Pharmaceutical (HK) Limited in July 2022.”

Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 19, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the N”

Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“September 19, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the N”

Sara Kenkare-Mitra was appointed as Independent Director at Unicycive Therapeutics, Inc..

“On September 5, 2023, Unicycive Therapeutics, Inc. (the “Company”) appointed Sara Kenkare-Mitra as an independent director.”

Unicycive Therapeutics, Inc. engaged Grassi & Co. CPAs, P.C. as its auditor.

“ugust 28, 2023, the Company appointed Grassi & Co. CPAs, P.C. (“ Grassi ”) as the Company’s new independent registered public accounting firm effective as of August 28, 2023, subject to Grassi’s completion of its client acceptance process. The Audit Committee of the board of directors of the Company approved the appointment of Grassi. During the fiscal year ended December 31, 2022 and the interim period from January 1, 2023 through June 30, 2023, neither the Company, nor anyone”

Unicycive Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $4.4 million, EPS $0.29 per share of common stock.

“Net loss attributable to common stockholders for the quarter ended June 30, 2023 was $4.4 million, or $0.29 per share of common stock”

Unicycive Therapeutics, Inc. shareholders approved Amendment and restatement of the 2021 Omnibus Equity Incentive Plan at the 2023-06-26 meeting.

“Proposal 5. The amendment and restatement of the 2021 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 9,474,374 959,587 10,645 2,655,662”

Unicycive Therapeutics, Inc. shareholders approved Reverse Stock Split Proposal at the 2023-06-26 meeting.

“Proposal 4. The Reverse Stock Split Proposal was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 12,679,613 412,810 7,840 3”

Unicycive Therapeutics, Inc. shareholders approved Nasdaq 20% Issuance Proposal at the 2023-06-26 meeting.

“Proposal 3. The Nasdaq 20% Issuance Proposal was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 8,129,197 236,958 11,705 2,655,661”

Unicycive Therapeutics, Inc. shareholders approved Ratification of appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-06-26 meeting.

“Proposal 2. The appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 13,057,585 30,776 11,904 1”

Unicycive Therapeutics, Inc. shareholders approved Election of four nominees for director to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. at the 2023-06-26 meeting.

“Proposal 1 . All of the four (4) nominees for director were elected to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the four (4) directors was as follows: Directors For Withhold Abstain Broker Non Vote Dr. Shalabh Gupta 10,308,931 0 135,675 2,655,662 Dr. Sandeep Laumas 9,453,731 0 990,876 2,655,661 Dr. John Ryan 9,298,925 0 1,145,681 2,655,662 Dr. Gaurav Aggarwal 10,307,961 0 136,646 2,655,661”

Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“May 17, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the Nasdaq”

Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.7 million, net income $14.6 million, EPS $0.97 per share of common stock.

“Renal Association Congress (ERA 2023) taking place in Milan, Italy from June 15-18, 2023. Financial Results for the First Quarter Ended March 31, 2023 Licensing revenues were $0.7 million for the quarter ended March 31, 2023 due to a licensing agreement executed in February 2023. Research and development expenses for the quarter ended March 31, 2023 were $3.0”

Unicycive Therapeutics, Inc. amended Amendment No. 1 with the investors named therein (effective 2023-04-06).

“On April 6, 2023, Unicycive Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 to the Securities Purchase Agreement originally dated as of March 3, 2023 (‘Amendment No. 1”) pursuant to which the Company and the investors named therein agreed that, with respect to the upcoming annual meeting of stockholders, the Company would be seeking stockholder approval of a reverse stock split of its common stock at a specific ratio within a range of 1-for-2 to 1-for-20 rather than 1-for-10 to 1-for-20.”

Unicycive Therapeutics, Inc. reported financial results for full year ended December 31, 2022.

“On March 31, 2023, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022 and provided a business update.”

Unicycive Therapeutics, Inc.: Gaurav Aggarwal, MD was appointed to the Board of Directors effective upon closing of the offering, with standard non-employee director compensation and indemnification (effective 2023-03-06).

“Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.”

Unicycive Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at $30 million (effective 2023-03-03).

“On March 3, 2023, Unicycive Therapeutics , Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors "), pursuant to which the Company agreed to issue and sell, in a private placement (the " Offering "), 30,190 shares of Series A-1 Convertible Preferred Stock, par value $0.001 per share (the " Series A-1 Preferred Stock "), for an aggregate offering price of $30 million.”

Gaurav Aggarwal was appointed as Director at Unicycive Therapeutics, Inc..

“effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.”

Unicycive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)).

“February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp”

Unicycive Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp”

Unicycive Therapeutics, Inc. entered into License Agreement with Lotus International Pte Ltd. valued at $750,000 (effective 2023-02-01).

“Unicycive Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) effective as of February 1, 2023 with Lotus International Pte Ltd. (“Lotus”) pursuant to which the Company licensed the exclusive right to develop, market and commercialize Renazorb® to Lotus in the Republic of Korea. Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for Renazorb® in the licensed territory. In addition, Lotus will have sole responsibility for the importation of the drug product from Unicycive and for the costs of commercialization of Renazorb® in the licensed territory. The Company will receive an upfront payment of $750,000”

Unicycive Therapeutics, Inc. terminated Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (effective 2023-01-08).

“On December 29, 2022, Unicycive Therapeutics, Inc. (the “Company”), provided notice of its termination, effective January 8, 2023, of the Capital on Demand Sales AgreementTM, dated as of August 15, 2022 (the “Sales Agreement”), by and between the Company and JonesTrading Institutional Services LLC (“JonesTrading”).”

Unicycive Therapeutics, Inc. reported financial results for three months ended September 30, 2022.

“On November 14, 2022, Unicycive Therapeutics, Inc. issued a press release announcing company highlights and financial results for the three months ended September 30, 2022.”